India, May 22 -- Assembly Biosciences, Inc (ASMB), a biotechnology company, on Friday announced that it has priced underwritten offering of 3.35 million shares of common stock at an offering price per share of common stock of $26.50, to raise around $100 million in gross proceeds.
Separately, the company announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). This would broaden the program into cholestatic liver diseases.
In pre-market activity on Nasdaq, the stock is trading 9.6 percent higher at $29.05.
In the offering, the company also offered certain investors p...